StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
December 01, 2021 13:08 ET
|
StacheStrong
VESTAL, NY, Dec. 01, 2021 (GLOBE NEWSWIRE) -- StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, and Barrow Neurological Foundation, announced they raised...
Brain Cancer Canada To Fund Barrier Breaking Chemistry Research Targeting Glioblastoma
November 30, 2021 08:30 ET
|
Brain Cancer Canada
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- A pioneering approach led by Prof. Patrick Gunning at the University of Toronto, leveraging advanced medicinal chemistry to help develop potential...
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
November 02, 2021 07:00 ET
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Nov. 02, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute and UC San Francisco announced the opening of a Phase 0 clinical trial to evaluate...
Brain Cancer Canada Funds Canadian Research Aiming To Treat Brain Cancer
October 24, 2021 09:00 ET
|
Brain Cancer Canada
TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) -- Brain Cancer Canada has issued a $100,000 grant to Canadian research exploring new frontiers of brain cancer treatment. Drs. Cynthia Hawkins and Roman...
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
October 19, 2021 18:12 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme
October 11, 2021 08:00 ET
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for...
Philogen Provides Corporate Update
September 29, 2021 04:58 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
September 20, 2021 12:00 ET
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, and...
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board
September 02, 2021 10:10 ET
|
Curative Biotechnology, Inc.
Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Expertise in Neurobiology Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) --...
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
July 21, 2021 05:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 21, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its...